Table 6.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 40 42 52 79 88 137 135 165 177 159
Tx with Antirejection Treatments 17 24 21 22 21 32 29 20 36 26
Antibodies Any in Category 70.6% 54.2% 57.1% 68.2% 52.4% 84.4% 89.7% 65.0% 63.9% 76.9%
ALG 17.6% 4.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 5.9% 4.2% 42.9% 18.2% 9.5% 0.0% 0.0% 5.0% 0.0% 0.0%
OKT3 64.7% 50.0% 42.9% 59.1% 47.6% 68.8% 55.2% 30.0% 41.7% 23.1%
Thymoglobulin 0.0% 0.0% 0.0% 0.0% 9.5% 37.5% 55.2% 40.0% 33.3% 57.7%
Zenapax 0.0% 0.0% 0.0% 0.0% 0.0% 12.5% 3.4% 5.0% 2.8% 11.5%
Simulect 0.0% 0.0% 0.0% 0.0% 0.0% 3.1% 3.4% 5.0% 0.0% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 11.1% 42.3%
Corticosteroids Any in Category 52.9% 50.0% 90.5% 63.6% 71.4% 75.0% 79.3% 90.0% 83.3% 84.6%
Steroids 52.9% 50.0% 90.5% 63.6% 71.4% 75.0% 79.3% 90.0% 83.3% 84.6%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 4.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 4.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.